Grafa News and Videos — Page 117

Biodexa (NASDAQ:BDRX) announced that 87 of a planned 168 subjects have been enrolled in its registrational Phase 3 Serenta trial evaluating eRapa in Familial Adenomatous Polyposis (FAP).

Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue of $18.99 million, up 28.8% year over year, with first-half revenue increasing 29.7% to $36.91 million.

Top Wealth Group Holding (NASDAQ:TWG) reported unaudited first-half 2026 revenue of $6.1 million, up 48% from $4.2 million a year earlier, driven mainly by expansion of its premium wine distribution business.

Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.

Intelligent Bio Solutions (NASDAQ:INBS) reported fiscal 2026 revenue of $4.2 million, up 38% year over year, driven by growth in its installed reader base and consumable cartridge sales.

Chemomab Therapeutics (NASDAQ:CMMB) reported second-quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine, with Chemomab shareholders expected to own about 32% of a combined company valued at $150 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human feasibility study of a colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery.

Veralto (NYSE:VLTO) signed a definitive agreement to acquire Cleanwater1 for $465 million, with an estimated net purchase price of $452 million after tax benefits.

Datavault AI (NASDAQ:DVLT) reported second-quarter 2026 revenue of $6.7 million, up $5 million or 287% year over year, as the company expanded its data monetization and tokenization platforms.

Antalpha (NASDAQ:ANTA) reported unaudited second-quarter 2026 revenue of $12.2 million, down 28% year over year, mainly due to lower technology financing fees following the wind-down of the Cango facility.